ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings For September, October

August 27, 1976

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

FDA Approves New Drug for Advanced Kidney Cancer

May 25, 2007

M.D. Anderson, SWOG To Use Web-Based Software To Expand Access To Trials.

September 29, 2000

DCPC Board Ponders Screening Recommendations: Should NCI Have Policies? If So, What Will They Be?

September 26, 1986

In Brief: NCI Terminates Straus’ Grant Following Site Visit Report Charging “Lack Of satisfactory Progress

February 19, 1982